PRME
Prime Medicine, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.83
+10.37%Sep 25, 2026, 12:46 UTC
Prime Medicine shares rose about 10.75% to $3.40 in after-hours trading.
Source:Sep 24, 2026, 20:01 UTC
The U.S. FDA cleared Prime Medicine's Investigational New Drug application for PM647 in alpha-1 antitrypsin deficiency.
Aug 6, 2026, 14:51 UTC
Prime Medicine, Inc. reported a Q2 2026 loss of $0.24 per share, in line with the Zacks Consensus Estimate, compared to a loss of $0.41 per share a year ago.
Source:Jul 8, 2026, 12:00 UTC
Prime Medicine announced a positive binding resolution of its arbitration with Beam Therapeutics, with the tribunal declaring PM647 within Prime Medicine's field and no monetary damages owed.
Jun 22, 2026, 12:00 UTC
The U.S. FDA granted RMAT designation to Prime Medicine's PM359 for treating chronic granulomatous disease.
Source:Jun 18, 2026, 12:00 UTC
Prime Medicine received clearance from New Zealand regulators for a clinical trial application for PM577a in H1069Q-mutated Wilson Disease.
Source: